U.S. Jury Finds AbbVie Liable for Misrepresentation in First AndroGel Verdict U.S. Jury Finds AbbVie Liable for Misrepresentation in First AndroGel Verdict

A federal jury in Chicago on Monday found AbbVie Inc fraudulently misrepresented the risks of its testosterone replacement drug AndroGel and ordered the drugmaker to pay $150 million in punitive damages.Reuters Health Information

Source: Medscape Medical News Headlines - July 25, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news